1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Celgene

Anonymous board for Celgene

Sort By:
Title
Replies Views
Last Message ↓
  1. anonymous
    Replies:
    0
    Views:
    865
  2. anonymous
    Replies:
    23
    Views:
    10,675
  3. anonymous
    Replies:
    9
    Views:
    2,799
  4. anonymous
    Replies:
    2
    Views:
    2,786
  5. anonymous
    Replies:
    0
    Views:
    1,309
  6. anonymous
    Replies:
    1
    Views:
    1,670
  7. anonymous
    Replies:
    5
    Views:
    1,418
  8. anonymous
    Replies:
    4
    Views:
    1,539
  9. anonymous
    Replies:
    1
    Views:
    893
  10. anonymous
    Replies:
    9
    Views:
    3,442
  11. anonymous
    Replies:
    0
    Views:
    950
  12. anonymous
    Replies:
    1
    Views:
    1,184
  13. anonymous
    Replies:
    44
    Views:
    20,050
  14. anonymous
    Replies:
    3
    Views:
    2,141
  15. anonymous
    Replies:
    30
    Views:
    6,907
  16. based_elon
    Replies:
    2
    Views:
    1,244
  17. anonymous
    Replies:
    22
    Views:
    6,826
  18. heavy_losses
    Replies:
    5
    Views:
    1,200
  19. Anonymous
    Replies:
    36
    Views:
    18,079
  20. anonymous
    Replies:
    1
    Views:
    1,289

Thread Display Options

Loading...